Volume 30, Number 11—November 2024
Research
Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021–February 2022
Figure 4

Figure 4. Violin plots of anti-RBD IgG and NT50 titer results by age group in a study of quantitative SARS-CoV-2 spike RBD and neutralizing antibody titers in previously infected persons, United States, January 2021–February 2022. A) Anti-RBD, n = 30,967; B) NT50, n = 744. Anti-RBD measured by Cov2Quant IgG (LabCorp, https://www.labcorp.com) and NT50 measured by PhenoSense SARS-CoV-2 Neutralizing Antibody Assay (Monogram Biosciences, https://monogrambio.labcorp.com). Horizontal lines in plots indicate first quantile, median, and third quantile; black dots indicates means. BAU, binding antibody units; NT50, 50% neutralization titer; RBD, receptor-binding domain.
1These co-senior authors contributed equally to this article.